Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.
Martijn P. Lolkema(National Institutes of Health), Sarah P. Blagden(Churchill Hospital), E. Jansen, Eric Angevin(Institut Gustave Roussy), Filip De Vos(University Medical Center Utrecht), Elizabeth Ruth Plummer, Ann Meulemans, Glen Clack(University of Sheffield), Martin Förster, Matthew Krebs(Christie's), Eric Ciamporcero(Roswell Park Comprehensive Cancer Center), Annegret Van der Aa, Timothy Perera(Deutz (Germany)), Marc Tjwa, Marion A.A. Libouban
Cited by 1
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Natural adjuvants: Endogenous activators of dendritic cells
|Nature Medicine|1999|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537